Vir Biotechnology Inc. (NASDAQ: VIR) reported Q3 EPS of ($0.85), $0.87 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $103.6 million versus the consensus estimate of $138.25 million.

As of September 30, 2021, excluding restricted cash, the Company had approximately $939.5 million in cash, cash equivalents and investments. Excluding restricted cash and its equity investment in Brii Biosciences, the Company had approximately $770.1 million in cash, cash equivalents and investments.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.